Supportive care encompasses managing symptoms and side effects before, during and after cancer treatment
Supportive care involves the management of the symptoms of cancer and the side effects of treatment across the whole course of cancer, from diagnosis through treatment to survivorship and end-of-life care. Cancer requires multimodality treatment, including chemotherapy, immunotherapy, radiotherapy and surgery, each of which can be used to palliate symptoms but may also have adverse effects that need managing. Likewise, supportive care needs multidisciplinary team support, including cancer specialist clinicians, nurses, pharmacists and allied health practitioners in addition to palliative care practitioners.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Mitchell S, Li X, Woods M, et al. Comparative effectiveness of granulocyte colony stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review. J Oncol Pham Pract 2016; doi: http://dx.doi.org/10.1177/1078155215625459 [Epub ahead of print].
- 2. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21: V232-V243.
- 3. Multinational Association of Supportive Care in Cancer, European Society for Medical Oncology. MASCC/ESMO antiemetic guideline 2016. Hillerød: MASCC, 2016 http://www.mascc.org/antiemetic-guidelines (accessed Mar 2016).
- 4. Olver IN, Eliott JA, Koczwara B. A qualitative study investigating chemotherapy-induced nausea as a symptom cluster. Support Care Cancer 2014; 22: 2749-2756.
- 5. Bandieri E, Romero M, Ripamonti C, et al. A randomised trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol 2016; 34: 436-442.
- 6. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014; 120: 1453-1461.
- 7. Ben-Aharon I, Gafter-Gvili PM, Leibovici L, et al. Interventions for alleviating cancer-related dyspnoea: a systematic review. J Clin Oncol 2008; 28: 2396-2404.
- 8. Sottnik JL, Keller ET. Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Curr Mol Med 2013; 13: 629-639.
- 9. Whitford HS, Olver IN. The multidimensionality of spiritual wellbeing: peace, meaning, and faith and their association with quality of life and coping in oncology. Psychooncology 2012; 21: 602-610.
- 10. Ramondetta LM, Sun C, Sorbone A, et al. Surprising results regarding MASCC members’ beliefs about spiritual care. Support Care Cancer 2013; 21: 2991-2998.
- 11. Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011; 8: 1079-1095.
- 12. Postow M, Wolchok J. Toxicities associated with checkpoint inhibitor immunotherapy. UpToDate 2016; 28 Mar. http://www.uptodate.com/contents/toxicities-associated-with-checkpoint-inhibitor-immunotherapy (accessed Apr 2016).
- 13. Carrera PM, Olver I. The financial hazard of personalized medicine and supportive care. Support Care Cancer 2015; 12: 3399-3401.
- 14. De Souza JA, Yap BJ, Hlubocky FJ, et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer 2014; 120: 3245-3253.
I have provided advice to Tesaro and Mundipharma. I am also a member of the MJA Editorial Advisory Committee.